CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION
Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | TUCKER, Thomas BRANCA, Danila RICARDO, Alonso MA, Zhong INGENITO, Raffaele YOUM, Hyewon BIANCHI, Elisabetta COSTANTINI, Willy XIONG, Yusheng WU, Chengwei HA, Sookhee BOYER, Nicolas KEREKES, Angela SHAHRIPOUR, Aurash DHAMNASKAR, Ketki |
| description | Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
L'invention concerne des composés polypeptidiques cycliques qui peuvent, par exemple, se lier spécifiquement à la subtilisine/kexine de proprotéine convertase humaine de type 9 (PCSK9), et de façon optionnelle peuvent également inhiber l'interaction entre la PCSK9 humaine et le récepteur des lipoprotéines de faible densité (LDLR) humain, ainsi que des compositions pharmaceutiques comprenant un ou plusieurs de ces composés. L'invention concerne également des méthodes permettant de faire baisser le taux de cholestérol LDL chez le patient le nécessitant, qui comprennent l'administration au patient d'un ou de plusieurs des composés polypeptidiques cycliques ou d'une composition pharmaceutique selon l'invention. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2020009805A3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2020009805A3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2020009805A33</originalsourceid><addsrcrecordid>eNrjZNBwjnT28XRWCPD3iQxwDQjxdHENVnDzD1IIcA72tlTw9PPwdPIM8fT342FgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8eH-RgZGBgYGlhYGpo7GxsSpAgCg7yUO</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION</title><source>esp@cenet</source><creator>TUCKER, Thomas ; BRANCA, Danila ; RICARDO, Alonso ; MA, Zhong ; INGENITO, Raffaele ; YOUM, Hyewon ; BIANCHI, Elisabetta ; COSTANTINI, Willy ; XIONG, Yusheng ; WU, Chengwei ; HA, Sookhee ; BOYER, Nicolas ; KEREKES, Angela ; SHAHRIPOUR, Aurash ; DHAMNASKAR, Ketki</creator><creatorcontrib>TUCKER, Thomas ; BRANCA, Danila ; RICARDO, Alonso ; MA, Zhong ; INGENITO, Raffaele ; YOUM, Hyewon ; BIANCHI, Elisabetta ; COSTANTINI, Willy ; XIONG, Yusheng ; WU, Chengwei ; HA, Sookhee ; BOYER, Nicolas ; KEREKES, Angela ; SHAHRIPOUR, Aurash ; DHAMNASKAR, Ketki</creatorcontrib><description>Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
L'invention concerne des composés polypeptidiques cycliques qui peuvent, par exemple, se lier spécifiquement à la subtilisine/kexine de proprotéine convertase humaine de type 9 (PCSK9), et de façon optionnelle peuvent également inhiber l'interaction entre la PCSK9 humaine et le récepteur des lipoprotéines de faible densité (LDLR) humain, ainsi que des compositions pharmaceutiques comprenant un ou plusieurs de ces composés. L'invention concerne également des méthodes permettant de faire baisser le taux de cholestérol LDL chez le patient le nécessitant, qui comprennent l'administration au patient d'un ou de plusieurs des composés polypeptidiques cycliques ou d'une composition pharmaceutique selon l'invention.</description><language>eng ; fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200402&DB=EPODOC&CC=WO&NR=2020009805A3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25568,76551</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200402&DB=EPODOC&CC=WO&NR=2020009805A3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>TUCKER, Thomas</creatorcontrib><creatorcontrib>BRANCA, Danila</creatorcontrib><creatorcontrib>RICARDO, Alonso</creatorcontrib><creatorcontrib>MA, Zhong</creatorcontrib><creatorcontrib>INGENITO, Raffaele</creatorcontrib><creatorcontrib>YOUM, Hyewon</creatorcontrib><creatorcontrib>BIANCHI, Elisabetta</creatorcontrib><creatorcontrib>COSTANTINI, Willy</creatorcontrib><creatorcontrib>XIONG, Yusheng</creatorcontrib><creatorcontrib>WU, Chengwei</creatorcontrib><creatorcontrib>HA, Sookhee</creatorcontrib><creatorcontrib>BOYER, Nicolas</creatorcontrib><creatorcontrib>KEREKES, Angela</creatorcontrib><creatorcontrib>SHAHRIPOUR, Aurash</creatorcontrib><creatorcontrib>DHAMNASKAR, Ketki</creatorcontrib><title>CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION</title><description>Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
L'invention concerne des composés polypeptidiques cycliques qui peuvent, par exemple, se lier spécifiquement à la subtilisine/kexine de proprotéine convertase humaine de type 9 (PCSK9), et de façon optionnelle peuvent également inhiber l'interaction entre la PCSK9 humaine et le récepteur des lipoprotéines de faible densité (LDLR) humain, ainsi que des compositions pharmaceutiques comprenant un ou plusieurs de ces composés. L'invention concerne également des méthodes permettant de faire baisser le taux de cholestérol LDL chez le patient le nécessitant, qui comprennent l'administration au patient d'un ou de plusieurs des composés polypeptidiques cycliques ou d'une composition pharmaceutique selon l'invention.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNBwjnT28XRWCPD3iQxwDQjxdHENVnDzD1IIcA72tlTw9PPwdPIM8fT342FgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8eH-RgZGBgYGlhYGpo7GxsSpAgCg7yUO</recordid><startdate>20200402</startdate><enddate>20200402</enddate><creator>TUCKER, Thomas</creator><creator>BRANCA, Danila</creator><creator>RICARDO, Alonso</creator><creator>MA, Zhong</creator><creator>INGENITO, Raffaele</creator><creator>YOUM, Hyewon</creator><creator>BIANCHI, Elisabetta</creator><creator>COSTANTINI, Willy</creator><creator>XIONG, Yusheng</creator><creator>WU, Chengwei</creator><creator>HA, Sookhee</creator><creator>BOYER, Nicolas</creator><creator>KEREKES, Angela</creator><creator>SHAHRIPOUR, Aurash</creator><creator>DHAMNASKAR, Ketki</creator><scope>EVB</scope></search><sort><creationdate>20200402</creationdate><title>CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION</title><author>TUCKER, Thomas ; BRANCA, Danila ; RICARDO, Alonso ; MA, Zhong ; INGENITO, Raffaele ; YOUM, Hyewon ; BIANCHI, Elisabetta ; COSTANTINI, Willy ; XIONG, Yusheng ; WU, Chengwei ; HA, Sookhee ; BOYER, Nicolas ; KEREKES, Angela ; SHAHRIPOUR, Aurash ; DHAMNASKAR, Ketki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2020009805A33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2020</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>TUCKER, Thomas</creatorcontrib><creatorcontrib>BRANCA, Danila</creatorcontrib><creatorcontrib>RICARDO, Alonso</creatorcontrib><creatorcontrib>MA, Zhong</creatorcontrib><creatorcontrib>INGENITO, Raffaele</creatorcontrib><creatorcontrib>YOUM, Hyewon</creatorcontrib><creatorcontrib>BIANCHI, Elisabetta</creatorcontrib><creatorcontrib>COSTANTINI, Willy</creatorcontrib><creatorcontrib>XIONG, Yusheng</creatorcontrib><creatorcontrib>WU, Chengwei</creatorcontrib><creatorcontrib>HA, Sookhee</creatorcontrib><creatorcontrib>BOYER, Nicolas</creatorcontrib><creatorcontrib>KEREKES, Angela</creatorcontrib><creatorcontrib>SHAHRIPOUR, Aurash</creatorcontrib><creatorcontrib>DHAMNASKAR, Ketki</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>TUCKER, Thomas</au><au>BRANCA, Danila</au><au>RICARDO, Alonso</au><au>MA, Zhong</au><au>INGENITO, Raffaele</au><au>YOUM, Hyewon</au><au>BIANCHI, Elisabetta</au><au>COSTANTINI, Willy</au><au>XIONG, Yusheng</au><au>WU, Chengwei</au><au>HA, Sookhee</au><au>BOYER, Nicolas</au><au>KEREKES, Angela</au><au>SHAHRIPOUR, Aurash</au><au>DHAMNASKAR, Ketki</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION</title><date>2020-04-02</date><risdate>2020</risdate><abstract>Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
L'invention concerne des composés polypeptidiques cycliques qui peuvent, par exemple, se lier spécifiquement à la subtilisine/kexine de proprotéine convertase humaine de type 9 (PCSK9), et de façon optionnelle peuvent également inhiber l'interaction entre la PCSK9 humaine et le récepteur des lipoprotéines de faible densité (LDLR) humain, ainsi que des compositions pharmaceutiques comprenant un ou plusieurs de ces composés. L'invention concerne également des méthodes permettant de faire baisser le taux de cholestérol LDL chez le patient le nécessitant, qui comprennent l'administration au patient d'un ou de plusieurs des composés polypeptidiques cycliques ou d'une composition pharmaceutique selon l'invention.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2020009805A3 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T06%3A26%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=TUCKER,%20Thomas&rft.date=2020-04-02&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2020009805A3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |